Covalon publishes results of ValGuard study in JAVA

Executive Summary

• Covalon Technologies Ltd. published peer-reviewed results in the Journal of the Association for Vascular Access (JAVA) demonstrating that its ValGuard line guard significantly reduces Central Line-Associated Bloodstream Infections (CLABSIs).
• The study, conducted at Children's Hospital at Montefiore, showed a 100% reduction in CLABSI rates in the Pediatric Critical Care Unit (PCCU) and a 53% reduction in acute care units following the implementation of ValGuard.
• The publication serves as third-party validation of the product's clinical efficacy, supporting Covalon's growth strategy in vascular access and surgical consumables.

Key Details

• Publication Venue: Journal of the Association for Vascular Access (JAVA).
• Study Title: "Evaluation of a Line Guard for Pediatric CLABSI Prevention: A Pre-Post Intervention Study."
• Study Location: Children's Hospital at Montefiore (nationally ranked U.S. pediatric hospital).
• Product: ValGuard, a transparent, single-use barrier device covering IV line connections and catheter hubs to prevent gross contamination.
• PCCU Results (Highest Compliance):
  • CLABSI rates decreased by 100%.
  • Pre-implementation average: 1.8 CLABSIs per 1,000 line days (over 15 months).
  • Post-implementation average: 0.0 CLABSIs per 1,000 line days (over 16 months).
• Acute Care Unit Results:
  • CLABSI rates decreased by 53%.
  • Pre-implementation average: 1.5 CLABSIs per 1,000 line days.
  • Post-implementation average: 0.7 CLABSIs per 1,000 line days.
• Additional Recognition: A scientific poster based on the study was selected as one of only four podium presentations from a pediatric-focused session at the Association for Vascular Access annual scientific meeting in September.
• Future Presentations: Findings will be showcased at the ANCC National Magnet Conference in October.

Notable Quotes

• Dr. Diana Lulgjuraj, PhD, RN, CPN, Clinical Nurse Scientist and Assistant Director of Nursing Research, Children's Hospital at Montefiore: "Our research shows that incorporating a line guard into our infection-prevention protocols can deliver meaningful benefits for children requiring central line access."
• Dr. Katherine Evely, Vice-President of Clinical Affairs, Covalon: "The publication of this study marks an important milestone for Covalon and for ValGuard. It represents novel, peer-reviewed evidence supporting the product's clinical impact when used as part of an infection-prevention bundle."